Doctoral Thesis
Refine
Year of publication
- 2017 (4) (remove)
Document Type
- Doctoral Thesis (4) (remove)
Has Fulltext
- yes (4)
Is part of the Bibliography
- no (4)
Keywords
- Proteomanalyse (2)
- Alzheimerkrankheit (1)
- Entsalzungstechniken (1)
- FLEXMAP 3D (1)
- Genomik (1)
- Herzinfarkt (1)
- Immunoprotemics (1)
- Maschinelles Lernen (1)
- Massenspektrometrie (1)
- Metabolomik (1)
Institute
- Interfakultäres Institut für Genetik und Funktionelle Genomforschung (UMG) (4) (remove)
Die vorliegende Arbeit adressiert die Nutzbarkeit des humanen Speichelproteoms als diagnostisches Instrument im Kontext einer oralen Mukositis bei Kopf- und Halskarzinoms. Als häufigste Nebenwirkung einer Radio(chemo)therapie kann die Mukositis therapielimitierend sein und hat für betroffene Patienten meist eine Einschränkung ihrer Lebensqualität zur Folge. Trotz der guten Verfügbarkeit von Speichel existieren wenige Studien, welche zeigen, dass das Speichelproteom für die Diagnostik einer Krankheit oder zur Therapieentscheidung nutzbar ist. Das hat unter anderem seinen Grund in der Komplexität der massenspektrometrischen Methode. Die erste Veröffentlichung (Golatowski et al. 2013) erarbeitete deshalb einen Standard in der Probengewinnung von Speichel. Als Ergebnis steht die Empfehlung zur Nutzung eines Paraffin-Kaugummis, aufgrund des hohen Speichelvolumens und der guten Vergleichbarkeit mit der nichtstimulierten Salivation beim identifizierten Proteom. In einer zweiten Veröffentlichung (Jehmlich & Golatowski et al. 2014) wurden C18 Mikrosäulen verschiedener Hersteller bezüglich ihres Einflusses auf die Proteinidentifizierung verglichen. Die Säulen sind notwendig für die Entsalzung und Aufreinigung eines Peptidgemisches. Mit allen verwendeten Säulen konnten ähnliche Ergebnisse erzielt werden, wobei die ZipTip® µC18 sowie C18 Systeme der OASIS® HLB μElution 96er Well Platte und TopTip® C18 Pipettenspitzen leicht überlegen sind. In der letzten Arbeit (Jehmlich et al. 2015) wurden die gewonnenen Erkenntnisse genutzt, um die Speichelproben von Patienten mit Kopf- und Halskarzinom zu untersuchen. Insgesamt zeigten wir die Möglichkeit, alterierte Proteine zwischen zwei Patientengruppen massenspektrometrisch zu detektieren. Mit den gefundenen Daten konnte demonstrieren werden, dass massenspektrometrische Techniken geeignet sind, um schon vor Behandlungsbeginn Patienten zu identifizieren, die für die Entwicklung einer oralen Mukositis prädisponiert sind. Es ist hierbei die Proteinklasse der Metalloproteinasen hervorzuheben, da diese für einen therapeutischen Ansatz gegen Mukositis interessant sind. In Zukunft werden jedoch größere und voraussichtlich multizentrische Studien erforderlich sein, um ausreichend große Patientenkohorten zusammenzustellen und die Klassifikation speziell für Patienten ohne Mukositisrisiko sensitiver zu gestalten.
Humanity is plagued by many diseases. Beside environmental influences, many --- if not all --- diseases are also subject to genetic predisposition and then display molecular alterations such as proteomic or metabolic aberrations. The elucidation of the molecular principles underlying human diseases is one of the prime goals of biomedical research. To this end, there has been an advent of large-scale omics profiling studies. While the field of molecular biology has experienced tremendous development, data analysis remains a bottleneck. In the context of this thesis, we developed a number of analysis strategies for different types of omics data resulting from different experimental settings. These include approaches for associations studies for plasma miRNAs and time-resolved plasma omics data. Furthermore, we devised analyses of different RNA-Seq transcriptome profiling studies coping with problems such as lack of replicates or multifactorial experimental design. We also designed machine learning frameworks for the identification of discriminatory biomolecular signatures analysing case-control or time-to-event data. All of the strategies mentioned above were developed and applied in the contexts of multi-disciplinary endeavours. They aided in the identification of plasma miRNAs associated with age, sex, and BMI as well as plasma miRNAs bearing potential as diagnostic biomarkers for non-alcoholic fatty liver disease (NAFLD). This thesis significantly contributed to a study demonstrating the utility of plasma miRNAs as prognostic biomarkers for major cardiovascular events such as ST-elevation myocardial infarction. Our approaches for analysing RNA-Seq data aided in the characterisation of murine models for Alzheimers disease and the transcriptional response of human gingiva fibroblasts to ionizing radiation exposure. Furthermore, the developed approaches were applied for studying a human model for thyrotoxicosis and for the successful identification of a multi-omics plasma biomarker signature of thyroid status. We are only beginning to understand the molecular principles underlying human diseases. The approaches and results presented in this thesis will contribute to improved understanding of biomolecular processes involved in common diseases such as Alzheimers disease, NAFLD, and cardiovascular diseases.
Transfusion-related acute lung injury (TRALI) is an adverse transfusion reaction and the major cause of transfusion-related mortality. The syndrome occurs within six hours after transfusion and is characterized by acute respiratory distress and the occurrence of a non-cardiogenic, bilateral lung edema. TRALI is almost entirely induced by leukocyte-reactive substances which are present in the blood product and get transferred to the recipient during transfusion. The majority of cases (~80%) is caused by leukocyte-reactive immunoglobulins and is accordingly classified as immune-mediated TRALI. The responsible antibodies are generated via alloimmunization and are directed against human leukocyte antigens of class I and II or human neutrophil alloantigens (HNA). Within the HNA class, HNA-3a antibodies have an exceptional clinical relevance as they are most frequently involved in severe and fatal TRALI cases. The high mortality was associated with their characteristic ability to induce a strong neutrophil aggregation response. The described clinical relevance of HNA-3a antibody-mediated TRALI motivates the screening for new strategies for preventive or acute pharmacologic intervention. Knowledge of the molecular pathomechanisms is a crucial prerequisite and thus, respective investigations are required. In order to achieve this goal, HNA-3a antibody-induced cytotoxicity and aggregation were assessed on the molecular level by usage of flow cytometry, the granulocyte agglutination test and by phosphoproteome analysis. The current study provides insight into molecular processes during HNA-3a antibody-induced neutrophil responses and is the first to assess neutrophils using global, gel-free phosphoproteome analyses. Accordingly, it is the first to provide neutrophil phosphoproteome data in the context of TRALI. Gel-free phosphoproteome analyses of primary neutrophils required the highly selective and sensitive phosphopeptide enrichment from stable and sufficiently large protein extracts. However, an appropriate workflow did not exist and was hence developed by sequential protocol optimization steps. The developed workflow was finally proven suitable for comparative gel-free phosphoproteomics when detecting the formyl-methionyl-leucyl-phenylalanine-induced activation of extracellular signal-regulated kinase 1/2 (ERK1/2) signaling in a proof-of-principle experiment. The following single parameter analyses were conducted to investigate neutrophils for their responses to HNA-3a antibodies in absence and presence of proinflammatory priming conditions. Results revealed that the direct stimulation of neutrophils with HNA-3a antibodies will likely not cause the induction of cytotoxic effector functions. In contrast, neutrophils react predominantly by aggregation, a process which is potentially mediated by integrins and causes a secondary, subthreshold activation of solely ERK2. Accordingly, only the neutrophil aggregation response could also be enhanced by an appropriate priming. Taken together, the single parameter analyses proved neutrophil aggregation as the main pathomechanism in HNA-3a antibody-mediated TRALI and thus, the underlying signaling pathways were investigated by global, gel-free phosphoproteomics. The following phosphoproteome analyses indicated the induction of a biphasic signaling during 30 minutes of HNA-3a antibody treatment and signaling pathways of Rho family GTPases could be associated with the first and the second phase. Additionally, the involvement of ERK signaling was indicated in the second phase and this result corroborated thus the data of the previous single parameter analyses. The comprehensive analysis of the identified signaling pathways revealed Rho, Rac and Cdc42 as central regulators and the specific inhibition of Rho in the following validating experiments led very intriguingly to a significant enhancement of HNA-3a antibody-mediated neutrophil aggregation. Hence, this result indicated a potential inhibitory effect of HNA-3a antibodies on Rho activity. Therefore, Rho inhibition was suggested to occur in parallel to an adhesion-inducing signaling pathway and might hence be involved in the stabilization of neutrophil aggregates in HNA-3a antibody-induced TRALI. The results from this doctoral thesis contributed to the generation of a new pathogenesis model for HNA-3a antibody-mediated TRALI. In this model, neutrophils respond to direct HNA-3a antibody exposure predominantly by homotypic aggregation. These potentially very stable and primed aggregates accumulate in the lung and are susceptible to parallel, proinflammatory stimulation. Subsequently, this cascade leads to full neutrophil activation and finally to TRALI induction.
Staphylococcus aureus (S. aureus) is the leading cause of serious diseases in human both from hospital and community associated infections. Some clinical manifestations of S. aureus infections are infective endocarditis (IE), osteoarticular infections, skin and soft tissue, pleuropulmonary, and device-related infections. In Germany, S. aureus is the second most common cause of hospital-acquired (HA) infections. About 16.7% of these nosocomial infections are caused by HA-MRSA clinical isolates. It has been a huge threat for the clinicians/scientists to control the emergence of such infections caused by S. aureus. S. aureus exhibits increasing virulence and resistance to various antibiotics, complicating prevention and treatment of infections. Eventually, active and passive vaccines might be the alternative strategy to deal with S. aureus related diseases. An effective S. aureus vaccine would provide great potential security and many societal benefits. However, so far vaccine trials have failed often due to limited number of available antigen candidates (monovalent/single antigen) in the clinical trials. Efforts to develop not only S. aureus vaccine but also prognosis or diagnosis tools are challenging tasks. That was the motivation point for the current thesis to identify potential antigen candidates for the aid of vaccine development using immunoproteomics approaches. From the earlier studies, passive immunisation with CP5, CP8, PNAG, ClfA, SdrG, alpha-hemolysin and active immunisation with IsdB, SEB, ClfA, CP5, CP8 were examined during preclinical trials and found to be the best examples for potential vaccine candidates. The antibody responses against S. aureus infections are heterogenous, still it is possible to identify the antibody signatures to a number of corresponding S. aureus antigens, whose abundance and presence could correlate to the disease state and may predict treatment outcome. To support this hypothesis, goals were set to develop and validate serological assay by indirect detection using suspension array technology (SAT). During the study, an antigen library of 140 recombinant S. aureus antigens was generated. Further serological assay were developed and validated to monitor the insights of antibody mediated humoral responses during S. aureus infection from various episodes of S. aureus infection. As an outcome, potential immunogenic antigen candidates were identified which may be used as candidates in active/passive vaccination and to stratify the patient. In total, three studies were carried out using serum and plasma samples from S. aureus nasal colonised healthy individuals (carriers and non-carriers) and bacteraemia patients (control, complicated and uncomplicated sepsis). Bead-based assays were performed and subsequent statistical analyses were done to identify immunogenic antigens that might discriminate between the different clinical status and outcome. Screening of healthy individuals (study-1) have shown significantly higher IgG responses against 14 antigens in S. aureus nasal carriers compared to non-carriers. Furthermore, the clonal complex 30 group of healthy carriers has shown significantly higher IgG responses against toxic shock syndrome toxin-1 (Tsst1) in comparison to non-clonal complex 30 healthy carriers. Study-2 have shown extensively higher IgG responses against 67 antigens in control samples compared to sepsis patients. 50% of the antigens eliciting different immune responses belonged to the extracellular components of S. aureus. The IgG responses against MSCRAMM proteins such as FnbA, FnbB, Efb-1 have been shown to be significantly higher in complicated sepsis. Study-3 have shown notably higher IgG responses against 8 antigens (Plc, SspB, IsaA, SEM, GlpQ, HlgC, SACOL0444, SACOL0985) at baseline in uncomplicated sepsis patients compared to patients subsequently developing complicated sepsis. In summary, the group of immunogenic antigens that have been identified in these studies using immunoproteomics approach could be a starting point for the development of S. aureus vaccines. Moreover, the suspension array technology approach facilitated the identification of new S. aureus antigen candidates in addition to earlier reports. The current results of this study support the hypothesis that it is possible to identify a serological response to potential S. aureus antigens that correlate to progression of S. aureus infections.